Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GB-0895 in Severe Uncontrolled Asthma
NCT07276724Phase 3Recruiting
- Sponsor
- Generate Biomedicines
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of GB-0895 in severe asthma, sponsored by Generate Biomedicines. Started Dec 2025; status: recruiting.
02
Drugs
GB-0895
03
Conditions
severe asthma
Beyond the preview
Go deeper on NCT07276724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276724.